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ABSTRACT 
Objective: Chitosan (CS)–tripolyphosphate (TPP)–nanoparticles (NPs) have been extensively studied during the past few decades due to their well-
recognized applicability in various fields. The present study attempts to optimise the development of these nanoparticles to enhance the 
percutaneous delivery of caffeine. 
Methods: CS-TPP-NPs were prepared via ionic cross-linking of CS and TPP and were characterized. The influence of several formulation conditions 
(CS: TPP mass ratio and concentration of caffeine) and process parameters (stirring speed, stirring time and ultra-sonication time) on the colloidal 
characteristics of CS-TPP-NPs were investigated and the resulting nanoparticles were characterized using scanning electron microscopy (SEM), 
transmission electron microscopy (TEM), Fourier transform infrared (FTIR) and x-ray diffraction (XRD) analyses. Physicochemical properties, 
including particle size, zeta potential and polydispersity index (PDI) were examined, and in vitro release studies were conducted to ascertain the 
release profile of caffeine from the nanoparticles. In addition, the colloidal stability of the prepared NPs was also assessed on storage. 
Results: Process parameters appeared to exert a significant effect on the physicochemical characteristics of the CS-TPP-NPs. The CS-TPP-NPs 
prepared under optimum conditions (CS concentration of 0.2 mg/ml, CS: TPP volume ratio of 25:12 ml, stirred at 700 rpm for 60 min, with 0.97 
mg/ml caffeine concentration and treatment with low ultra-sonication for 30 min) had shown a mean particle size of ~143.43±1.69 nm, zeta 
potential of+43.13±1.10 mV, PDI of ~0.30±0.01. A drug loading capacity and encapsulation efficiency of 48.89% and 60.69%, respectively, were 
obtained. Cumulative release study for drug-loaded CS-NPs was significantly (p<0.001, paired t-test) higher (58.7% caffeine released) compared to 
control formulation (41.5% caffeine released) after 72 h. Stability studies conducted for 28 d showed that caffeine-loaded CS-NPs degraded much 
quicker when stored at 25 ⁰C than 4 ⁰C. It was also noted that caffeine-loaded CS-NPs in the freeze-dried form were unstable as the surface charge of 
nanoparticles dropped from positive zeta potential to-3.55 mV within 2 d at 4 ⁰C and at 25 ⁰C, surface charge dropped to-3.16 mV within 14 d of the 
experiment. 
Conclusion: Chitosan (CS)–tripolyphosphate (TPP)–nanoparticles (NPs) appear to be a promising strategy to achieve sustained percutaneous 
delivery of caffeine. 
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Androgenic alopecia is a common disorder of scalp hair follicles, 
effecting men and women, resulting in the gradual thinning and 
increased loss of hair from the scalp. In men, the degree of hair loss 
follows a well-defined pattern, with a receding hairline and thinning 
of the crown, usually going on to develop completely bald areas. 
Women tend to show a generalized thinning of the crown, but rarely 
leading to complete baldness. A number of genetic and 
environmental factors are thought to contribute to androgenic 
alopecia, however, dihydrotestosterone, (DHT), has been found to be 
the effector hormone for this type of hair loss, causing a continuous 
shortening of hair growth cycle (anagen phase) and eventually 
miniaturized, hair follicles [1].  
Caffeine is well known as a mild stimulant of the central nervous 
system where it is transported with blood after its absorption in the 
stomach and small intestine [5]. Consumption of caffeine can reduce 
drowsiness and restoring alertness, cognitive function, particularly 
vigilance, mood and perception of fatigue [6]. Caffeine has high 
biological activity [2] and an ability to penetrate the skin barrier [3, 
4], hence is being increasingly used in cosmetics applications. For 
example, caffeine has been used as an active compound in anti-
cellulite products because it prevents excessive accumulation of fat 
in cells [7, 8]. It stimulates the degradation of fats during lipolysis 
through inhibition of the phosphodiesterase activity [9]. In addition, 
caffeine has potent antioxidant properties. Studies revealed that use 
of caffeine in the formulation of sunscreen cosmetics raises its 
protective effect against UV radiation, reduces the formation of free 
radicals in skin cells and could be useful in preventing UV-induced 
skin cancers [10, 11]. Caffeine has been shown to demonstrate 
beneficial effects on androgenic alopecia [12], due to an influence on 
hair growth mechanisms. Caffeine act as a phosphodiesterase 
inhibitor, increasing cAMP levels in cells, counteracting the effects of 
the DHT hormone and therefore stimulating cell metabolism to 
promote hair growth [12].  
Chitosan nanoparticles have been widely investigated as drug 
carriers, with the potential to improve bioavailability from the skin 
[13], enhanced efficacy [14] and the ability to achieve sustain drug 
release [15]. Minoxidil loaded in chitosan nanoparticle [32] for 
example has been utilized to achieve sustain drug release about 
twice more than previous studies using microparticles [16]. In 
addition, nanoparticles have shown the potential for delivering 
drugs via the follicles [17, 18]. The particles can aggregate in the 
follicular opening and penetrate along the follicular duct when 
nanoparticles containing active ingredients are applied onto the skin 
surface. As a result, the active ingredients can be delivered deep into 
the skin and into the systemic circulation by using nanoparticles for 
therapeutics aim. Chitosan is a biodegradable polymer, thus 
presents an advantage in pharmaceutical and cosmetic applications 
since it can completely be eliminated from the body by natural 
metabolic pathways [20]. Chitosan is obtained by partial 
deacetylation of chitin. The amino group in chitosan has a pKa value 
of ∼6.5, thus, chitosan is positively charged and soluble in acidic to a 
neutral solution. Ionic gelation method has been extensively used in 
the preparation of chitosan nanoparticles as it has numerous 
advantages such as preparation of small size and compact 
structured particles [21], use of aqueous media [22], and control of 
colloidal characteristics of the nanoparticles by the variation of 
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formulation and process parameters [23]. The method involves ionic 
cross-linking between cations of chitosan and anion such as sodium 
tripolyphosphate (TPP) [24]. As reported by Calvo et al., positively 
charged nanoparticles are formed through inter-and intra-cross-
linking of the amino groups (–NH3+) of chitosan with negatively 
charged phosphate groups (–PO4-) [24]. According to Huang et. al and 
Yang et. al, the particle size distribution and zeta potential of 
nanoparticles greatly depends on the mixing procedure of chitosan 
and TPP and their stoichiometry, as well as chitosan and TPP 
concentration [25, 26]. 
In this present work, TPP is used as a cross-linker in the preparation 
of chitosan nanoparticles loaded with caffeine. The effects of stirring 
rate, CS: TPP volume ratio and the effect concentration of drugs on 
to optimized the nanoparticles were examined by characterization 
of the mean diameter size of particles, PDI and zeta potential. The 
resulting nanoparticles were also characterized using SEM, TEM, 
FTIR and XRD analyses. In vitro release studies and colloidal stability 
of the resulting nanoparticles were conducted to evaluate their use 
as a carrier systems for caffeine. 
MATERIALS AND METHODS 
Materials 
Chitosan (CS, deacetylation degree of 85% and low molecular 
weight), sodium tripolyphosphate (TPP), phosphate buffered 
saline (PBS), and caffeine, M. wt 194.19 g/mol were purchased 
from Sigma-Aldrich Co. Ltd (Malaysia). Acetic acid glacial (Grade 
AR, CH3COOH, M. Wt 60, 05 g/mol) was obtained from 
Friendemann Schmidt. High-performance liquid chromatography 
(HPLC)-grade acetonitrile was obtained from Fischer Scientific 
Korea Ltd (Seoul, Korea). All other chemicals used were of 
analytical grade. 
Preparation of unloaded CS-NPs and caffeine-loaded CS-NPs 
Nanoparticles (NPs) were prepared by inducing the gelation of 
chitosan solutions with crosslink agent, sodium tripolyphosphate 
(TPP) [28]. 0.2% low molecular weight CS solution was prepared in 
1% acetic acid while 0.1% TPP was dissolved in distilled water. CS-
NPs were spontaneously formed upon addition of TPP into CS 
solution. Caffeine was dissolved in the 0.1% TPP solution. Caffeine-
loaded CS-NPs was formed when TPP containing drug solution was 
added drop-wise into 25 ml of CS solution under magnetic stirring 
for 30 min at room temperature. The resulting caffeine-loaded CS-
NPs were subjected to ultra-sonication process for a few minutes. 
The caffeine-loaded CS-NPs were then separated from their 
suspension by ultracentrifugation at 30,000 rpm, 25 °C for 30 min 
and subsequently lyophilized (Scanvac Cool Safe 110, Chemoscience, 
Thailand) at −90⁰C for 24 h. 
Nanoparticles characterization 
Size, zeta potential and PDI 
The resulting pellets co-loaded NPs after ultracentrifugation were 
collected and suspended in distilled water. The average size, PDI and 
the zeta potential was determined using “Zetasizer Nano ZS” 
(Malvern Instrument, UK) equipment. The measurements of samples 
were done in triplicates. 
Encapsulation efficiency and loading capacity 
The resulting supernatant was filtered and analyzed using a HPLC 
validated method. Various standard solutions of caffeine were 
prepared and subjecting to reversed phase HPLC. 
The effective efficiency (EE %) and loading capacity (LC %) were 
measured corresponding to standard calibration curves. The 
effective efficiency (EE %) was calculated using the equation below. 
 
LC% =  [
QtheoreticalQobtained
Qlyophilized
] x 100   (2) 
Where Qtheoretical was the amount of caffeine initially added to prepare 
chitosan nanoparticles, Qobtained was the quantified amount of caffeine 
and Qlyophilized was lyophilized caffeine-loaded nanoparticles. 
SEM and TEM analysis 
The morphology of nanoparticles and size distribution was observed 
using scanning electron microscope (FEI Quanta 200 SEM) and 
transmission electron microscope (Hitachi H-8100 TEM). The 
lyophilized caffeine-loaded CS-NPs was dispersed in acetone 
solution and sonicated for approximately 15 min. For SEM, caffeine-
loaded CS-NPs in acetone solution were spread on a glass plate and 
dried at room temperature. For TEM, caffeine-loaded CS-NPs in 
acetone solution was dropped on a copper grid and dried at room 
temperature. The dried caffeine-loaded CS-NPs were then coated 
with gold and placed under observation stage and images were 
observed under, at 10,000 to 100,000 magnifications. 
Fourier transform infrared spectroscopy (FT-IR) and X-ray 
powder diffraction (XRD) analysis 
The chemical structure of CS, unloaded CS-NPs and caffeine-loaded 
CS-NPs were scanned using an FT-IR spectrophotometer (Spectrum 
100; Perkin Elmer, USA). Briefly, a small quantity (2–3) mg of CS was 
mixed with 78 mg potassium bromide (KBr) and compressed to 
form a transparent pellet using a hydraulic press. A similar 
procedure was used to prepare transparent pellets of unloaded CS-
NPs and caffeine-loaded CS-NPs. Finally, the resulting pellets were 
scanned in transmission mode in a spectral region of 4000–400 cm−1 
using a resolution of 4 cm−1 and 32 co-added scans. The crystalline 
or amorphous nature of CS, unloaded CS-NPS and drug-loaded CS-
NPs were confirmed by using X-ray diffractometer (Shidmazu, 
XRD6000X, Japan). All the samples were scanned from 0 to 120. 
Drug release studies 
CS-NPs loaded with caffeine and 5 ml PBS solution (pH 7.4) were 
added into a dialysis sac (MWCO: 0.5-1.0 kDA) and was placed in 
100 ml PBS at 37 ˚C and maintained under water bath, shaken at 200 
rpm. The analysis was performed in triplicates for each sample. At 
specific time intervals, 3 ml medium was taken out and then 
replaced with fresh PBS. The concentration of released caffeine was 
determined by HPLC analysis. 
Stability studies 
A standard amount of nanoparticles was suspended in PBS solution 
(pH 7.4) and stirred for 1 hour. All samples was placed in a tube and 
covered with aluminum foil. Each sample of caffeine loaded CS-NPs 
were kept separately at 4 ⁰C and 25 ⁰C for 28 d. Samples were 
analyzed at predetermined time intervals of 0, 1, 3, 5 d and the every 
week after for up to one month. For each time interval, the average 
size, PdI and zeta potential of the sample were measured. 
HPLC analysis 
The concentration of caffeine was quantified by using reversed-
phase HPLC method. A reverse-phase C18 column (Shimadzu, 4.6 
mm x 150 mm, 5µ. m) is used. The mobile phase used in this 
analysis consists of water/acetonitrile mixture at ratio 35:65 
(v/v). The volume of sample injected into the liquid 
chromatography is 10 µl with flow rate of 1.0 ml/min. UV 
detection is performed at 285 nm. The linearity is measured from 
the calibration curve of standard solutions containing 0.1-1.0 
mg/ml (n=10) of caffeine. The precision and accuracy of this 
method is expressed as coefficient of variation (%CV) and relative 
standard error (% E) in accordance to FDA guidelines. 
Statistical analysis  
All data are presented as mean±standard deviation. Data were 
analyzed with either paired t-tests or independent t-test and ANOVA, 
followed by a Tukey’s post-hoc analysis. For the analysis of particle 
size, zeta potential, EE, and LC of NPs, a p-value of less than 0.05 was 
considered to indicate a significant difference. For the data obtained 
from ex vivo permeation, drug skin retention, and skin thickness, a p-
value of less than 0.001∗∗∗ was considered to indicate a significant 
difference. 
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RESULTS AND DISCUSSION 
Particle size, PDI and zeta potential 
The effects of magnetic stirring speed on particle size, PDI and zeta 
potential are summarized in fig. 1 (A, B and C). As shown in fig. 1A, 
the particle size of CS-NPs decreased from 617.43 nm to 411.27 nm 
as the speed of stirring was increased from 300 rpm to 700 rpm at 
constant time of stirring. The size of particles is expected to reduce 
with increasing agitation [27]. Sufficient stirring can accelerate the 
dispersion of TPP in CS solution and the increased shear force helps 
to narrow size distribution [28]. 700 rpm speed of stirring was 
observed to improve mixing and create a more uniform 
environment for NPs formation, therefore contributing to a smaller 
average particles size. 
As for PDI and zeta potential, both increased with increasing stirring 








Fig. 1: Mean profile of effect of magnetic stirring on physicochemical properties of CS-NPs. A. Effect on particle size; B. Effect on PDI; C. 
Effect on zeta potential. (mean±SD, n=3) 
 
Stirring time has also been shown to have a significant effect on 
the particle size. The effect of stirring time on particle size was 
observed for four different durations of time; 15, 30, 60 and 120 
min (fig. 2). The resulting data indicates the influence of stirring 
time, revealing a gradual decrease in the mean particle size from 
421.60±3.47 to 319.30±2.31 nm, when stirring was increased from 
15 to 60 min. This may be due to an improved dispersion of TPP in 
chitosan solution at longer stirring times, as the increased shear 
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force helps to narrow the dispersity index. However, when the 
stirring time was increased to 120 min, the mean particle size of 
NPs was seen to increase to 489.70±1.71 nm. Nie and co-workers 
[29] demonstrated that an increase in the stirring time encourages 









Fig. 2: Mean profile of effect of stirring time on physicochemical properties of CS-NPs, A. Effect on particle size; B. Effect on PDI; C. Effect on 
zeta potential. (mean±SD, n=3) 
 
The effects of different volume ratios of CS to TPP ranging from 
25:5 to 25:15 on the physicochemical properties of CS-NPs are 
shown in fig. 3. When the volume ratio of CS/TPP was increased 
from 25:5 to 25:10, the particle size and PDI demonstrated an 
increase from 584 to 650 nm in size distribution and PDI in the 
range 0.6 to 0.8. This indicates a broader nanoparticle size 
distribution. One possible explanation is that lowering the TPP 
volume reduces the ability of the system to crosslink, thus 
lowering the number of nanoparticles produced. Particle size 
decreases to a value of 352.50 nm when the volume ratio of 
CS/TPP is increased to 25:12. This narrow particle size 
distribution suggests a better ionic interaction [30] between CS 
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and TPP at this ratio, leading to an enhanced degree of cross-
linking. The particle size was then shown to increase to 506.53 
nm with increased in a volume ratio of CS/TPP to 25:15. At 
higher levels of TPP, a larger particle of nanoparticles was 
formed most likely due to the repulsion of charges since there 








Fig. 3: Mean profile of effect of different volume of TPP added on physicochemical properties of CS-NPs. A. Effect on particle size; B. Effect 
on PDI; C. Effect on zeta potential. (mean±SD, n=3) 
 
To investigate the influence of ultra-sonication on the 
physicochemical characteristics of NPs, the prepared CS-TPP-NPs 
dispersion was subjected to low-efficiency ultra-sonic processor 
over a series of time periods from 5 to 30 min. The resulting data 
(fig. 4) indicates a linear decrease in the average particle diameter 
of CS-TPP-NPs with increasing sonication time. The ultra-
sonication process has been shown to reduce the average of 
particle size because it can break up the cluster formation of 
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nanoparticles and help to scatter the nanoparticles into base fluids 
[31]. The mean diameter of dispersed NPs is reduced by 
approximately 50% after 30 min of ultra-sonication, from 
231.30±5.80 to 142.20±0.61 nm. Moderate use of ultra-sonication 
could be able to reduce the particle size significantly via the 
disruption of particle aggregations, however, extensive ultra-
sonication may cause severe fragmentation of the compact 








Fig. 4: Mean profile of effect of ultra-sonication time on physicochemical properties of CS-NPs. A. Effect on particle size; B. Effect on PDI; C. 
Effect on zeta potential. (mean±SD, n=3) 
 
The effect of different caffeine concentrations on particle size and 
PDI are summarized in fig. 5. Different formulations of caffeine-
loaded nanoparticles were prepared by adding a different amount of 
drug into TPP solution which was then added drop wised into the CS 
solution. After stirring, these solutions were subjected to 
ultrasonication for 15 min. As the concentration of caffeine was 
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increased from 0.32 mg/ml to 0.97 mg/ml, the size of particles 
increased from 143.43 nm to 230.13 nm, indicating denser 
complexes forming at higher concentrations, due to the formation of 
larger self-assembled nanoparticles.  
The zeta potentials of unloaded CS-NPs are shown in fig. 1 and 2, 
and caffeine-loaded NPs in fig. 3. All values are favourably 









Fig. 5: Mean profile of effect of different concentration of caffeine on physicochemical properties of CS-NPs. A. Effect on particle size; B. 
Effect on PDI; C. Effect on zeta potential. (mean±SD, n=3) 
 
Encapsulation efficiency and loading capacity 
The encapsulation efficiency (EE) and loading capacity (LC) of 
different formulations were determined and are shown in table 1. 
Increasing caffeine concentration from 0.016 mg/ml to 0.970 mg/ml 
in the formulations, results in a higher EE and LC in the range of 
3.32%-48.89% and 0.13%-60.69% respectively.  
Any further increase in caffeine concentration results in a 
decrease in EE and LC to 39.10% and 50.50% respectively. An 
increase in the EE of caffeine may indicate that the reaction 
mixture becomes more viscous at higher drug concentration, 
which would tend to increase the forces opposing the extensive 
incorporation of caffeine inside the polymer matrices and hence 
reducing the EE caffeine [34]. 
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 Table 1: Encapsulation efficiency and loading capacity of different concentration of caffeine-loaded CS-NPs formulations (mean±SD, n=3) 
Concentration of caffeine (mg/ml) EE% LC% 
0.016 3.32 0.13 
0.032 5.01 0.41 
0.320 33.50 16.08 
0.970 48.89 60.69 
1.620 39.10 50.50 
 
Morphological observation 
The morphological characteristics of caffeine-loaded CS-NPs were 
examined using SEM and TEM analysis and the results are shown 
in fig. 6 and 7, respectively. The results suggest that caffeine-
loaded CS-NPs are relatively smooth and spherical with a diameter 
varying from 50-150 nm. All the NPs from SEM and TEM images 
were smaller than the hydrodynamic sizes determined by light 
scattering because of the drying and vacuum process. The variable 
morphology of caffeine-loaded CS-NPs may be attributed to the 
variation in the inter-or intra-particulate interaction of caffeine-
loaded CS-NPs, may contribute to this morphological diversity. 
Both TEM and SEM micrographs revealed that some particle 
aggregation may be due to the freezing and drying stress from the 
freeze-drying process, and this aggregation contributes to the 






Fig. 6: Electron micrographs obtained by SEM for the morphological and size analysis of lyophilized caffeine-loaded CS-NPs. A. 60 000 
magnification; B. 100 000 magnification 
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Fig. 8: FT-IR spectra of (a) CS, (b) unloaded CS-NPs, and (c) caffeine-loaded CS-NPs 
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FTIR and XRD analysis 
The FTIR spectra of low molecular CS, unloaded CS-NPs, and 
caffeine-loaded CS-NPs are shown in fig. 8. The results indicate that 
the intense characteristic peaks of CS (fig. 4(a)) appeared at 3398.61 
cm−1 (-OH stretching), 2881.03 cm−1 (-CH stretching), 1651.11 cm−1, 
1599.61 cm−1 (-NH2 stretching), 1324.50 cm−1 (C-N stretching), 
1088.61 cm−1 (C-O-C stretching) and 564.62 cm−1 (pyranoside ring 
stretching vibration). The characteristic peaks of unloaded CS-NPs 
(fig. 4 (b)) representing–OH group appeared at 3389.90 cm−1. The–
NH2 bending vibration shifts from 1651.11 cm−1 and 1599.61 cm−1 to 
1651.92 cm−1 and 1553.11 cm−1, which indicates that some 
interaction between NH3+groups of CS and TPP occurred within the 
nanoparticles [33]. For caffeine-loaded CS-NPs (fig. 4 (c)), the–OH 
peak (3399.58 cm−1) becomes broader, indicating that bonding 
action is enhanced because of the reaction between CS and caffeine 
[34]. A new peak appeared at 1702.29 cm−1 indicating carbonyl 
group (C=O) present in caffeine. In addition, the peak at 1324.50 
cm−1 (C-N bending) in the CS spectra (fig. 4(a)) shifted to 1385.64 
cm−1 in the caffeine-loaded CS-NPs spectra (fig. 4(c)). This indicates 
interaction between the C=O group of caffeine and the primary 
amide group of CS. Hence, these results indicate that caffeine was 
successfully loaded into the CS-NPs. 
The crystal phase identification of the studied samples was 
carried out using X-ray diffraction (XRD). It is a non-destructive 
technique widely used for the characterization of crystalline 
materials. The X-RD of chitosan, unloaded CS-NPs and caffeine-
loaded CS-NPs were determined and shown in fig. 9. CS exhibit 
two characteristic peaks at 2θ of 10.7˚ and 20.3˚ (fig. 5(a)), 
indicating some degree of crystallinity, however the degree of 
crystallinity was less than its nanoparticle form (fig. 5(b)). 
Unloaded CS-NPs showed several sharp peaks at 2θ of 23.3˚, 
27.0˚ and 28.6˚ indicating a more crystalline nature of 
nanoparticles. And the characteristic peaks of caffeine-loaded 
CS-NPs exhibit sharp peak only at 2θ of 11.9˚, indicating a degree 
of crystallinity which was less than the unloaded CS-NPs. This 
may be the result of caffeine existing as a molecular dispersion 
in the polymeric nanoparticles, which in turn reduces the 





Fig. 9: XRD patterns of (a) CS, (b) unloaded CS-NPs and (c) caffeine-loaded CS-NPs 
 
Drug release studies 
The in vitro cumulative release profiles of caffeine from CS-NPs 
and aqueous solution of drug (control formulation) in PBS solution 
(pH 7.4) are depicted in fig. 10. There is an increment of drug 
release for both formulations within the 72 h duration of the 
study. Both formulations showed sustained release of caffeine 
throughout the 72 h duration. However, the release of caffeine 
from CS-NPs was significantly (p<0.001, paired t-test) higher 
compared to the release of caffeine from control formulation. 
Within the first 8 h of study, caffeine released was 24.9% and 
16.3% from CS-NPs and the control formulation respectively. At 
the end of 72 h, approximately, 58.7% of caffeine was released 
from CS-NPs and 41.5% of caffeine was released from the control 
formulation. Caffeine-loaded in CS-NPs with a smaller size possess 
a greater surface-to-volume ratio, resulting in a higher released 
and penetration compared to caffeine in aqueous solution. In 
addition, drug release is less rapid in amorphous nanoparticles 
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than in crystalline particles. Lack of crystallinity suggests better 
drug dispersion and increased drug–matrix interactions, leading 
to the conclusion that if slower release kinetics are required, 
reduced crystallinity is favoured [37]. 
  
 
Fig. 10: Release profile of the caffeine from the caffeine-loaded CS-NPs formulation compared to an aqueous solution of the drug (control 








Fig. 11: Stability study on A. particle size; B. PDI; C. zeta potential of caffeine-loaded CS-NPs in PBS solution stored in solution at 25 ˚C and 4 ˚C 
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Stability studies of nanoparticles in solution form 
Degradation times of CS-NPs loaded with caffeine in PBS stored at 
25 ˚C and 4 ˚C observed over a 28 d period are shown in fig. 11. 
Particle sizes were measured as a function of time throughout the 
period. In both cases, particle sizes and standard deviations 
increased with time, similar to that described in previous studies 
[36]. The results also showed that the sample stored at room 
temperature degraded much quicker than that stored in the 
refrigerator. This increased in particle sizes may be due to particle 
agglomeration. However, the results obtained confirmed that the 
caffeine-loaded CS-NPs were stable throughout the 28 d period with 
the particle size, PDI and zeta potential remaining within the 
accepted nanoparticle range. 
Stability studies of caffeine-loaded CS-NPs in freeze-dried form were 
also conducted at both temperatures for 28 d. The results are shown 
in fig. 12. The mean particle size of caffeine-loaded CS-NPs shows 
much greater values, above 1000 nm. Freezing exerts a substantial 
destabilizing stress on nanoparticles resulting in two phases of 
separation; one which contains ice and another concentrated 
viscous phase containing the nanostructures and other formulation 
constituents. This high particulate concentration, together with the 
ice crystals, may lead to aggregation, and in some cases, an 
irreversible fusion of nanoparticles [38, 39].  
In addition, lyophilized caffeine-loaded CS-NPs showed instability as 
the zeta potential dropped to negative values when kept at both 
temperatures. Zeta potential of caffeine-loaded CS-NPs dropped from 
5.60 to-3.50 mV within 2 d when kept at 4 ˚C, and dropped from 5.60 
to-3.16 mV at 25 ˚C both within 14 d of the experiment. The decline in 
the zeta potential of caffeine-loaded CS-NPs was possibly due to of 
particle aggregation. Particle clumping may have occurred upon 
pelleting after centrifugation process. The aggregation in 
nanoparticles could be explained by electrolytes within the PBS 
solution, surrounding the nanoparticles reducing the surface charge of 
particles, hence reducing the ionic interaction between the ionized 








Fig. 12: Stability study on A. particle size; B. PDI; C. zeta potential of caffeine-loaded CS-NPs stored in freeze-dried form at 25 ˚C and 4 ˚C 
Sahudin et al. 




The current study demonstrated a significant influence of the 
preparation conditions (CS: TPP volume ratio, the concentration of 
the drug and stirring speed) on the mean particle size, zeta potential 
and polydispersity index of CS-TPP-NPs. The controlling parameters 
were clearly identified in this present study in order to produce CS-
TPP-NPs with optimal characteristics. The hydrophilic drug, caffeine 
was successfully incorporated in CS-NPs by cross-linking method 
with good EE (60.69%) and LC (48.89%). Caffeine-loaded CS-NPs 
was also found to release significantly more caffeine than the control 
formulation within the 72 h experiment duration. Finally, stability 
studies conducted for 28 d showed that caffeine-loaded CS-NPs 
degraded much quicker when stored at 25 ˚C than 4 ˚C and was more 
stable in solution than in its freeze-dried form. 
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